



## PUBLIC INTEREST IN THE OFF-LABEL USE OF GLUCAGON-LIKE PEPTIDE 1 AGONISTS (OZEMPIC) FOR COSMETIC WEIGHT LOSS

Abdallah Marey Aboshhran<sup>1\*</sup>, Saeed Ali Alqahtani<sup>2</sup>, Yasser Mesfer Alqhtani<sup>3</sup>, Ahmed Saleh Alharthi<sup>4</sup>, Abdulrahman Hussain Fawwaz Kahl<sup>5</sup>, Khaled Mohsin Ismail Khormi<sup>6</sup>

<sup>1</sup>\*Technician Pharmacy, aaboshhran@moh.gov.sa, King Fahd General hospital Jeddah

<sup>2</sup>Pharmacist, Salqahtani165@moh.gov.sa, King Fahd General hospital Jeddah

<sup>3</sup>Technician pharmacy, Yalqhtani@moh.gov.sa, King Fahd General hospital Jeddah

<sup>4</sup>Pharmacist, aalharthi59@moh.gov.sa, King Fahd General hospital Jeddah

<sup>5</sup>Pharmacy Technician, akahl@moh.gov.sa, Irada and Mental Health Hospital in Al-Kharj

<sup>6</sup>Pharmacy Technician, kmkhormi@moh.gov.sa, Irada and Mental Health Hospital in Al-Kharj

**\*Corresponding Author:** Abdallah Marey Aboshhran

\*Technician Pharmacy, aaboshhran@moh.gov.sa, King Fahd General hospital Jeddah

### Abstract

The off-label use of Glucagon-like Peptide 1 (GLP-1) agonists, such as Ozempic, for cosmetic weight loss has garnered significant public interest in recent years. This essay explores the implications of this trend on public health, ethical considerations, and regulatory frameworks. The introduction provides a background on GLP-1 agonists and their approved medical uses, while the methods section outlines the various sources consulted to gather information for this essay. The results section highlights the benefits and risks associated with off-label use of GLP-1 agonists for weight loss. The discussion section delves into the ethical considerations surrounding this practice, including potential risks and benefits, while the conclusions summarize the main points raised in the essay. Finally, the reference list provides a comprehensive list of reputable sources consulted for this essay.

**Keywords:** GLP-1 agonists, Ozempic, off-label use, weight loss, public interest

### Introduction

GLP-1 agonists, such as Ozempic, are a class of medications primarily used to treat type 2 diabetes by improving blood sugar control and promoting weight loss. These drugs work by mimicking the effects of GLP-1, a hormone produced in the gut that stimulates insulin secretion and reduces appetite. In recent years, there has been growing interest in the off-label use of GLP-1 agonists for cosmetic weight loss among individuals looking to achieve rapid and significant weight reduction for aesthetic purposes. This trend has raised concerns within the medical community regarding the safety, efficacy, and ethical implications of using these medications for non-approved indications.

Glucagon-like peptide 1 (GLP-1) agonists, such as Ozempic (semaglutide), are medications primarily approved for the treatment of type 2 diabetes. These drugs work by stimulating insulin secretion, reducing glucagon production, and promoting satiety, leading to improved glycemic control and potential weight loss. However, the off-label use of GLP-1 agonists, including Ozempic, for cosmetic weight loss purposes raises several considerations:

**Efficacy and Safety:** While GLP-1 agonists have demonstrated efficacy in weight loss, their off-label use for cosmetic purposes lacks sufficient clinical evidence. The safety and long-term effects of using Ozempic solely for cosmetic weight loss remain uncertain. Clinical trials and studies typically focus on the medication's approved indications, and the risk-benefit profile may differ when used off-label.

**Healthcare Professional Guidance:** Initiating and monitoring treatment with GLP-1 agonists should be done under the guidance of a healthcare professional. They can assess the patient's overall health, evaluate potential risks and benefits, and provide personalized recommendations. Off-label use without medical supervision may lead to inappropriate dosage, inadequate monitoring, and unrecognized side effects.

**Regulatory Considerations:** Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have not approved GLP-1 agonists, including Ozempic, for cosmetic weight loss. Off-label use involves using a medication in a manner not specified in its approved labeling. While physicians can prescribe medications off-label when they believe it is in the patient's best interest, it is important to consider the ethical and legal aspects of such practice.

**Side Effects and Adverse Events:** Like any medication, GLP-1 agonists can have side effects and adverse events. These may include gastrointestinal symptoms (such as nausea, vomiting, and diarrhea), pancreatitis, gallbladder disease, and potential cardiovascular effects. The risks and benefits of off-label use must be carefully evaluated, considering the individual's health status and potential contraindications.

**Lifestyle Modifications:** Weight loss achieved through GLP-1 agonists alone may not be sustainable in the absence of lifestyle modifications. A comprehensive approach involving a healthy diet, regular exercise, and behavioral changes is essential for long-term weight management. Relying solely on medication for cosmetic weight loss may lead to unrealistic expectations and overlook the importance of lifestyle interventions.

Public interest in using GLP-1 agonists off-label for cosmetic weight loss may stem from the desire for quick and effortless solutions. However, it is crucial to prioritize evidence-based medicine, prioritize patient safety, and seek guidance from qualified healthcare professionals. Engaging in open discussions with healthcare providers can help individuals understand the potential risks, benefits, and alternatives for achieving their weight loss goals in a safe and sustainable manner.

## **Methods**

To investigate the public interest in the off-label use of GLP-1 agonists for cosmetic weight loss, a comprehensive search of the literature was conducted. Peer-reviewed articles, medical journals, government reports, and reputable websites were consulted to gather information on the benefits, risks, ethical considerations, and regulatory frameworks associated with this practice. The sources were critically analyzed to provide a balanced and evidence-based discussion on the topic.

## **Results**

The off-label use of GLP-1 agonists for cosmetic weight loss has shown promising results in some individuals, with significant reductions in body weight reported in clinical trials. These medications have been found to suppress appetite, increase feelings of fullness, and promote weight loss in patients with obesity. However, this practice is not without risks, as adverse effects such as nausea, vomiting, diarrhea, and pancreatitis have been reported with the use of GLP-1 agonists. Additionally, the long-term safety and efficacy of using these medications for weight loss purposes remain unclear.

## **Discussion**

The public interest in the off-label use of GLP-1 agonists for cosmetic weight loss raises several ethical considerations. While individuals have the autonomy to make choices about their health and bodies, using medications for non-approved indications can pose risks to their overall well-being. There is a lack of robust evidence supporting the safety and efficacy of using GLP-1 agonists for weight loss outside of their approved indications, which raises concerns about the potential harm that may result from this practice. Furthermore, promoting weight loss for cosmetic reasons may

perpetuate societal pressures and unrealistic body standards, leading to body image issues and disordered eating behaviors.

### Conclusions

In conclusion, the public interest in the off-label use of GLP-1 agonists for cosmetic weight loss underscores the need for a balanced approach to healthcare decision-making. While these medications show promise in promoting weight loss, the risks associated with their off-label use must be carefully considered. Ethical guidelines, regulatory oversight, and informed consent are essential to ensure that individuals make informed choices about their health and well-being. Further research is needed to evaluate the long-term effects of using GLP-1 agonists for weight loss and to establish guidelines for their safe and appropriate use.

### Referrals

- 1 .Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet*. 2009;374(9701):1606-1616. doi:10.1016/s0140-6736(09)61375-1
- 2 .Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int J Obes (Lond)*. 2013;37(11):1443-1451. doi:10.1038/ijo.2013.120
- 3 .Liraglutide for Weight Loss NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK285521/>. Accessed September 13, 2021.
- 4 .Blonde L, Russell-Jones D. The safety and efficacy of liraglutide, a glucagon-like peptide-1 agonist, in the treatment of type 2 diabetes. *Expert Opin Drug Saf*. 2009;8(2):129-135. doi:10.1517/14740330803469265
- 5 .Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. *J Med Chem*. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- 6 .Tivi S. Semaglutide - the Quest for the Holy Grail of Weight Loss. *Pharm J*. February 2021:2021.
- 7 .Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ*. 2012;344. doi:10.1136/bmj.d7771
- 8 .Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A Preprandial Rise in Plasma Ghrelin Levels Suggests a Role in Meal Initiation in Humans. *Diabetes*. 2001;50(8):1714-1719. doi:10.2337/diabetes.50..1714
- 9 .Knudsen LB. Glucagon-Like Peptide-1 Agonists for the Treatment of Type 2 Diabetes: Differences and Similarities. *Eur J Intern Med*. 2014;25(5):407-414. doi:10.1016/j.ejim.2014.03.006
- 10 .Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med*. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519